Leerink Partnrs Has Bearish Forecast for Hologic Q3 Earnings

Hologic, Inc. (NASDAQ:HOLX) – Leerink Partnrs reduced their Q3 2025 earnings estimates for shares of Hologic in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the medical equipment provider will earn $1.12 per share for the quarter, down from their prior forecast of $1.13. The consensus estimate for Hologic’s current full-year earnings is $4.27 per share. Leerink Partnrs also issued estimates for Hologic’s Q4 2025 earnings at $1.12 EPS and FY2025 earnings at $4.29 EPS.

Several other research analysts have also recently weighed in on the stock. Jefferies Financial Group assumed coverage on shares of Hologic in a report on Tuesday, December 10th. They set a “hold” rating and a $85.00 price target on the stock. Needham & Company LLC restated a “buy” rating and set a $90.00 price target on shares of Hologic in a research report on Monday, January 13th. Morgan Stanley lowered their price objective on shares of Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Mizuho decreased their price target on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Finally, UBS Group increased their price objective on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Seven equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.92.

Hologic Trading Up 1.2 %

NASDAQ HOLX opened at $71.19 on Thursday. The company has a current ratio of 3.69, a quick ratio of 3.03 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $16.07 billion, a P/E ratio of 21.38, a PEG ratio of 2.40 and a beta of 0.97. The business has a fifty day simple moving average of $74.30 and a 200 day simple moving average of $78.31. Hologic has a 12 month low of $68.61 and a 12 month high of $84.67.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business had revenue of $987.90 million during the quarter, compared to the consensus estimate of $978.25 million. During the same quarter last year, the firm posted $0.89 EPS. Hologic’s revenue was up 4.5% compared to the same quarter last year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. State Street Corp raised its position in Hologic by 0.8% in the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after purchasing an additional 81,057 shares during the period. FMR LLC increased its holdings in shares of Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after buying an additional 2,174,093 shares during the period. The Manufacturers Life Insurance Company lifted its stake in shares of Hologic by 0.7% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 2,554,032 shares of the medical equipment provider’s stock valued at $208,051,000 after acquiring an additional 18,774 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. boosted its stake in shares of Hologic by 8.6% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,466,888 shares of the medical equipment provider’s stock valued at $200,952,000 after purchasing an additional 195,285 shares during the period. Finally, Nordea Investment Management AB boosted its stake in shares of Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock valued at $159,911,000 after purchasing an additional 544,889 shares during the period. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, COO Essex D. Mitchell sold 24,856 shares of the firm’s stock in a transaction dated Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total transaction of $1,897,507.04. Following the transaction, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at approximately $2,134,237.38. This trade represents a 47.06 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 1.88% of the stock is owned by company insiders.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.